Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The US Food and Drug Administration (FDA) approved Yeztugo, a long-awaited semi-annual injectable treatment for the ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its ...

The Food and Drug Administration approved a new vaccine to prevent HIV infection, lenacapavir, a long-acting injection, which ...

The United States Food and Drug Administration (FDA) has approved a twice-a-year drug to be used to prevent HIV.

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...